Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication

Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections, what is the Influence of XDR Phenotype on Outcomes?

  • Montero, María Milagro|||0000-0001-5991-6804
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Knobel Freud, Hernando|||0000-0003-3186-6416
  • Molas, Ema
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Siverio Pares, Ana Cristina
  • Prim, Núria|||0000-0002-5283-0917
  • Segura, Concepción
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Grau, Santiago|||0000-0002-8428-1836
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
This study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31.9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3.07, 95% confidence interval (CI), 1.73-5.46), septic shock (HR 1.75, 95% CI, 1.12-2.75), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12-1.38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0.39, 95% CI, 0.24-0.62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0.56, 95% CI, 0.33-0.93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Isolates

  • Montero, María Milagro|||0000-0001-5991-6804
  • Domene-Ochoa, Sandra|||0000-0003-4315-9794
  • López-Causapé, Carla
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Luque, Sonia|||0000-0002-3215-320X
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Campillo, Núria
  • Padilla Leon, Eduardo
  • Prim, Núria|||0000-0002-5283-0917
  • Ferrer Alapont, Lorena|||0000-0003-2152-4754
  • Grau, Santiago|||0000-0002-8428-1836
  • Oliver, Antonio|||0000-0001-9327-1894
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
The aim of this study was to compare the efficacy of intermittent (1-h), extended (4-h), and continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant (XDR) sequence type (ST) 175 isolates with different susceptibilities to C/T (MIC = 2 to 16 mg/L) in a 7-day hollow-fiber infection model (HFIM). C/T in continuous infusion achieved the largest reduction in total number of bacterial colonies in the overall treatment arms for both C/T-susceptible and -resistant isolates. It was also the only regimen with bactericidal activity against all three isolates. These data suggest that continuous C/T infusion should be considered a potential treatment for infections caused by XDR isolates, including nonsusceptible ones. Proper use of C/T dosing regimens may lead to better clinical management of XDR infections. IMPORTANCE Ceftolozane-tazobactam (C/T) is an antipseudomonal antibiotic with a high clinical impact in treating infection caused by extensively drug-resistant (XDR) isolates, but resistance is emerging. Given its time-dependent behavior, C/T continuous infusion can improve exposure and therefore the pharmacokinetic/pharmacodynamic target attainment. We compared the efficacy of intermittent, extended, and continuous C/T infusion against three XDR ST175 isolates with different C/T MICs by means of an in vitro dynamic hollow-fiber model. We demonstrated that C/T in continuous infusion achieved the largest reduction in bacterial density in the overall treatment arms for both susceptible and resistant isolates. It was also the only regimen with bactericidal activity against all three isolates. Through this study, we want to demonstrate that developing individually tailored antimicrobial treatments is becoming essential. Our results support the role of C/T level monitoring and of dose adjustments for better clinical management and outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model

  • Montero, María M.
  • Domene-Ochoa, Sandra|||0000-0003-4315-9794
  • López-Causapé, Carla
  • Luque, Sonia|||0000-0002-3215-320X
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Campillo, Núria
  • Padilla Leon, Eduardo
  • Prim, Núria|||0000-0002-5283-0917
  • Ferrer Alapont, Lorena|||0000-0003-2152-4754
  • Angulo-Brunet, Ariadna|||0000-0002-0583-1618
  • Grau, Santiago|||0000-0002-8428-1836
  • Oliver, Antonio|||0000-0001-9327-1894
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
Ceftolozane/tazobactam (C/T) has emerged as a potential agent for the treatment of extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. As it is a time-dependent antimicrobial, prolonged infusion may help achieve pharmacokinetic/pharmacodynamic (PK/PD) targets. To compare alternative steady-state concentrations (Css) of C/T in continuous infusion (CI) against three XDR P. aeruginosa ST175 isolates with C/T minimum inhibitory concentration (MIC) values of 2 to 16 mg/L in a hollow-fiber infection model (HFIM). Duplicate 10-day HFIM assays were performed to evaluate Css of C/T in CI: one compared 20 and 45 mg/L against the C/T-susceptible isolate while the other compared 45 and 80 mg/L against the two C/T-non-susceptible isolates. C/T resistance emerged when C/T-susceptible isolate was treated with C/T in CI at a Css of 20 mg/L; which showed a deletion in the gene encoding AmpC β-lactamase. The higher dosing regimen (80 mg/L) showed a slight advantage in effectiveness. The higher dosing regimen has the greatest bactericidal effect, regardless of C/T MIC. Exposure to the suboptimal Css of 20 mg/L led to the emergence of C/T resistance in the susceptible isolate. Antimicrobial regimens should be optimized through C/T levels monitoring and dose adjustments to improve clinical management.